Vonoprazan for treating Helicobacter pylori infection

Infections

Gastrointestinal tract

1 April 2020

Published on 01 Apr 2020
Last Updated on 01 Apr 2020

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended listing vonoprazan on the Medication Assistance Fund (MAF) for treating Helicobacter pylori infection due to low clinical need, uncertain clinical effectiveness and unfavourable cost-effectiveness compared to alternate treatment options.

Vonoprazan for H pylori infection (1 Apr 2020) [PDF, 40 KB]

Vonoprazan for H pylori infection PES (1 Apr 2020) [PDF, 34 KB]